Walleye Trading’s AbCellera Biologics ABCL Stock Holding History

Walleye Trading’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.71K	Buy	600 +200	+50%	+$978	﹤0.01%	3864
2026 Q1	$1.4K	Sell	400 -96,800	-100%	-$348K	﹤0.01%	4011
2025 Q4	$332K	Buy	97,200 +10,700	+12%	+$47.8K	﹤0.01%	3085
2025 Q3	$435K	Buy	+86,500	New	+$381K	﹤0.01%	2835
2024 Q1	–	Sell	-15,700	Closed	-$89.6K	–	4671
2023 Q4	$89.6K	Sell	15,700 -1,700	-10%	-$7.88K	﹤0.01%	4185
2023 Q3	$80K	Buy	17,400 +5,800	+50%	+$35.3K	﹤0.01%	4056
2023 Q2	$74.9K	Buy	11,600 +11,100	+2,220%	+$75.7K	﹤0.01%	3847
2023 Q1	$3.77K	Buy	+500	New	+$4.54K	﹤0.01%	4537
2022 Q4	–	Sell	-9,300	Closed	-$92K	–	4904
2022 Q3	$92K	Buy	+9,300	New	+$102K	﹤0.01%	4076

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Walleye Trading's ABCL Position: Q2 2026 in Review

Walleye Trading increased its AbCellera Biologics (ABCL) stake by 481% in Q2 2026, buying an estimated $181K and bringing the position to 44,609 shares worth $350K. The position accounts for ﹤0.01% of the portfolio, ranked #2867.

Walleye Trading first reported a position in ABCL in Q3 2022 and has held it in 8 quarters since. The position peaked at $361K in Q3 2022. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Walleye Trading held 44,609 shares of AbCellera Biologics worth $350K as of Q2 2026.
Walleye Trading bought 36,931 AbCellera Biologics shares in Q2 2026, an estimated $181K.
AbCellera Biologics made up ﹤0.01% of Walleye Trading's portfolio in Q2 2026, its #2867 holding.
Walleye Trading first reported a position in AbCellera Biologics in Q3 2022 and has held it in 8 quarters since.
Walleye Trading's AbCellera Biologics position peaked at $361K in Q3 2022.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.